… Atezolizumab and bevacizumab have become the new standard of care for the first-line
treatment of advanced HCC. We report our first experience with atezolizumab and bevacizumab …

… We present real-world data on the efficacy and safety of atezolizumab plus bevacizumab in
patients with aHCC who have received at least one prior systemic therapy from 13 centers in …

… The dosing of atezo/bev in our cohort was as per the IMbrave trial, that is, atezolizumab 1200
mg and bevacizumab 15 mg/kg intravenously every 3 weeks. Treatment was discontinued …

… with unresectable or metastatic HCC treated with atezolizumab plus bevacizumab as part
of routine clinical care. Patients were treated in 11 tertiary referral centers in Germany (n = 55), …

… Patients treated with atezolizumab/bevacizumab in the first … Among the 7 patients receiving
atezolizumab/bevacizumab as a … patients from tertiary university centers in a Western country. …

… Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for …
Clinical efficacy of atezolizumab plus bevacizumab for the treatment of advanced hepato-…

… Abstract: Real-world data regarding treatment with atezolizumab plus bevacizumab in high-…
HCC received atezolizumab plus bevacizumab treatment at four tertiary hospitals. High-risk …

… safety of atezolizumab and bevacizumab in treating … tertiary cancer center, 111 patients
with Barcelona Clinic Liver Cancer stage B or C HCC received atezolizumab and bevacizumab …

… Our data suggest that the combination of bevacizumab and atezolizumab is associated
with tumor regression in select patients with NETs, without new or concerning safety signals. …

Background Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for
unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies …